Now accepting Telehealth appointments. Schedule a virtual visit.

Multi-Cancer Early Detection Screening Specialist

Russak Personalized Medicine

Internal Medicine, Pediatrics & Geriatrics located in Greenwood Village, CO

Multi-Cancer Early Detection Screening Q & A

What is multi-cancer early detection?

Multi-cancer early detection enables you to proactively screen for many cancers at once, increasing the chances of finding cancer early. 

What is the importance of multi-cancer early detection?

Finding cancer early is important to improve treatment outcomes and survival.1

The vast majority of cancers show no symptoms until later stages, when treatment options may be limited.2 Today, there are 5 recommended cancer screening tests that together only account for  1 in 4 diagnosed cancers in patients over 50 years of age.3,4 71% of cancer deaths are caused by cancers not commonly screened for today.5, 6 When cancers are diagnosed early before they have had a chance to spread, the overall 5-year survival rate is 4x higher than when diagnosed in later stages.1, 7 The most important cancer is the one that you or your loved one may have - and beating it starts with knowing you have it.

How do I get a multi-cancer early detection screening?

We are excited to offer the Galleri™ multi-cancer early detection test, a first-of-its-kind test that can detect more than 50 types of cancer8,9 through a simple blood draw for our adult patients with an elevated risk for cancer, such as those aged 50 or older. It is intended to be used in addition to and not replace other cancer screening tests we recommend.10 

How does the multi-cancer early detection test work?

All cells in your body release DNA into the bloodstream, but DNA from cancer cells is different from the DNA of healthy cells.12 The Galleri test looks at the DNA in your blood to determine if any of it may have come from cancer cells, and the results can point to where in the body the cancer is coming from with high accuracy to help guide your next steps

See Important Safety Information

  

REFERENCES

1. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data, Nov

2018 Submission. Includes persons aged 50-79 diagnosed 2006-2015 “Early/Localized” includes invasive localized tumors that have not spread beyond organ

of origin, “Late/Metastasized” includes invasive cancers that have metastasized beyond the organ of origin to other parts of the body.

2. Cancer Facts and Figures 2021 https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf

3. Modeled detection extrapolated to 2020 US population ages 50–79

4. Calculated by internal analysis using data from SEER*Stat Database: Incidence which represents 34.6% of US population - SEER 18 Regs Research Data,

Nov 2018 Submission. Includes persons aged 50–79 diagnosed 2006-2015. Pinsky. J Med Screen.

2012;19(3):154-156: 33% of lung cancers in US among National Lung Screening Trial eligible population. Screening includes methods with United States

Preventive Services Task Force (USPSTF) A, B, or C rating (breast, colon, cervical, prostate, and lung). 5. Modeled detection extrapolated to 2020 US population ages 50–79. Screening includes methods with United States Preventive Services Task Force

(USPSTF) A, B, or C rating (breast, colon, cervical, prostate, and lung), and assumes screening is available for all prostate, breast, cervical, and colorectal

cancer cases and 33% of lung cancer cases (based on estimated proportion of lung cancers that occur in screen-eligible individuals older than 40 years).

6. Data on file from Surveillance, Epidemiology, and End Results (SEER) 18 Regs Research Data, Nov 2017 Submission. Includes persons aged 50–79.

Estimated deaths per year in 2020 from American Cancer Society Cancer Facts and Figures 2020. Available at: www.cancer.org/content/dam/cancer-org/

research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf

of origin, “Late/Metastasized” includes invasive cancers that have metastasized beyond the organ of origin to other parts of the body.

7. Noone AM, Howlader N, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2015, National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/

csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER website April 2018.

8. Amin MB, et al. (Eds). American Joint Committee of Cancer (AJCC) Cancer Staging Manual (8th edition)

9. Klein E, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test. Oral presentation at: American Association for Cancer Research; April, 2021; LB013.

10. The Galleri test does not detect all cancers nor does it measure your genetic risk of developing cancer in the future. It should be used in addition to guideline-recommended cancer screenings such as mammography, colonoscopy, PSA, or cervical cancer screening.